Identification
- Composition (DCI)
- irbesartanhydrchlorothiazide
- Manufacturer
- PHI
- ATC code
- C09DA04
- Presentation
- Boite de 30
- Schedule / Reimb.
- A
- Hospital price
- 81.10 MAD
Indications
Traitement de l'hypertension artérielle essentielle lorsque l'effet d'une monothérapie reste insuffisant. Traitement initial en cas d'hypertension prononcée, lorsqu'un contrôle rapide de la pression artérielle (en termes de jours ou de semaines) est de première importance clinique.
Find an open pharmacy
On-call pharmacies near you
About IRPHI PLUS 150 MG / 12.5 MG
IRPHI PLUS 150 MG / 12.5 MG is marketed in Morocco by PHI and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of IRPHI PLUS 150 MG / 12.5 MG, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about IRPHI PLUS 150 MG / 12.5 MG
Answers to common questions from Moroccan patients about this drug.